Satellos Bioscience Inc. (MSLE)
NASDAQ: MSLE · Real-Time Price · USD
8.50
0.00 (0.00%)
At close: Oct 2, 2026, 4:00 PM EDT
8.45
-0.05 (-0.59%)
After-hours: Oct 2, 2026, 7:30 PM EDT
Satellos Bioscience Employees
As of December 31, 2025, Satellos Bioscience had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year.
Employees
21
Change (1Y)
4
Growth (1Y)
23.53%
Revenue / Employee
n/a
Profits / Employee
-$1,648,095
Market Cap
178.75M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | 4 | 23.53% | 18 | 3 |
| Dec 31, 2024 | 17 | 1 | 6.25% | 14 | 3 |
| Dec 31, 2023 | 16 | - | - | 4 | 12 |
Related Stocks
| Company Name | Employees |
|---|---|
| Coherus Oncology | 144 |
| Adagene | 128 |
| MediWound | 121 |
| Nkarta | 106 |
| Precision BioSciences | 67 |
| ALX Oncology Holdings | 48 |
| Anavex Life Sciences | 34 |
| Cue Biopharma | 29 |
MSLE News
- 4 days ago - Satellos Completes Enrollment In Phase 2 Forazapadin Trial For DMD - Nasdaq
- 4 days ago - Satellos announces enrollment completed for BASECAMP - TheFly
- 4 days ago - Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy - Financial Post
- 4 days ago - Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy - GlobeNewsWire
- 10 days ago - Satellos Bioscience (MSLE) Gains FDA IND Approval, Eyes Phase 2 Trial for FSHD - GuruFocus
- 10 days ago - Satellos Gets FDA Clearance For Forazapadin In FSHD; Phase 2 Study Planned - Nasdaq
- 10 days ago - Satellos announces U.S. FDA cleared IND application for forazapadin - TheFly
- 10 days ago - Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development - GlobeNewsWire